Recombinant Human VSIG4 Short Isoform His Tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9816-VS

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
9816-VS-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

Q9Y279-3

Conjugate

Unconjugated

Applications

Bioactivity

View all VSIG4 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human VSIG4 protein
Arg20-Pro189, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Arg20

Predicted Molecular Mass

20 kDa

SDS-PAGE

24-33 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC).
The ED50 for this effect is 0.5-3 μg/mL.

Scientific Data Images for Recombinant Human VSIG4 Short Isoform His Tag Protein, CF

Recombinant Human VSIG4 Short Isoform His Tag Protein Bioactivity

Recombinant Human VSIG4 Short Isoform His Tag Protein Bioactivity

Recombinant Human VSIG4 (Catalog # 9816-VS) inhibits IFN-gamma secretion by human peripheral blood mononuclear cells in the presence of anti-CD3 antibody. The ED50 for this effect is 0.5-3 μg/mL.

Formulation, Preparation and Storage

9816-VS
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 200 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VSIG4

VSIG4 (V-set and immunoglobulin domain containing 4), also known as CRIg and Z39IG, is a type I transmembrane protein of the B7 family within the Ig superfamily that is expressed only in tissue-resident macrophages (1-4). The gene is located on the X chromosome (2). The human VSIG4 precursor includes a signal sequence, an extracellular domain (ECD) containing a V-type and a C2-type Ig domain, a transmembrane domain and a cytoplasmic domain (3). Splice isoforms lacking all or part of the cytoplasmic domain, the C2-type Ig domain and/or the transmembrane domain have been identified (5). This product is a VSIG4 isoform lacking C2-type Ig domain (Short Isoform). The human VSIG4 ECD shares 84% aa identity with canine VSIG4. Within the IgV domain, it shares 90%, 80% and 78% aa identity with bovine, mouse and rat VSIG4, respectively; these animals lack the C2-type domain. VSIG4 is specifically expressed on macrophages in the thymic medulla, peritoneum, alveoli, synovia, adipose and heart, liver Kupffer cells, placental Hofbauer cells, and atherosclerotic foam cells (1-4, 6-9). It is absent on infiltrating macrophages (8). VSIG4 is a complement receptor that binds C3b and iC3b fragments, internalizes them to recycling endosomes, and is recycled to the cell surface (4, 6). It contributes significantly to innate immunity by binding and phagocytosis of complement-opsonized invading pathogens (4, 8, 10). Binding of either native or recombinant soluble VSIG4 to C3b inhibits complement amplification through the alternative, but not classical, pathway (10, 11). VSIG4 is also a negative regulator of mouse and human T cell activation (2). Although VSIG4 engagement may activate NF kappa B and thus be pro-inflammatory in some cases, many of its activities are important in resolving, rather than initiating, inflammation (1, 2, 7, 10, 11). VSIG4 negatively regulates macrophage activation by reprogramming mitochondrial pyruvate metabolism (12). VSIG4 is overexpressed in ovarian cancers compared with that in benign tumors (13). VSIG4 expression in multiple myeloma is an independent indicator of poor prognosis, implying a possible therapeutic target for immunotherapy for multiple myeloma (14).

References

  1. He, J.Q. et al. (2008) Mol. Immunol. 4041.
  2. Vogt, L. et al. (2006) J. Clin. Invest. 116:2817.
  3. Langnaese, K. et al. (2000) Biochim. Biophys. Acta 1492:522.
  4. Helmy, K. et al. (2006) Cell 124:915.
  5. Small, A.G. et al. (2016) Swiss Med. Wkly. 146:w14301.
  6. Tanaka, M. et al. (2008) Clin. Exp. Immunol. 154:38.
  7. Lee, M-Y. et al. (2006) J. Leukoc. Biol. 80:922.
  8. Gorgani, N.N. et al. (2008) J. Immunol. 181:7902.
  9. Walker, M.G. (2002) Biochim. Biophys. Acta 1574:387.
  10. Wiesmann, C. et al. (2006) Nature 444:217.
  11. Katschke, K.J. et al. (2007) J. Exp. Med. 204:1319.
  12. Li, J. et al. (2017) Nat Commun. 8:1322.
  13. Byun, JM. et al. (2017) Int J Gynecol Cancer. 27:872.
  14. Roh, J. et al. (2017) Oncotarget. 8:58122.

Long Name

V-Set and Immunoglobulin Domain Containing 4

Alternate Names

Z39IG

Entrez Gene IDs

11326 (Human); 278180 (Mouse); 312102 (Rat); 102144784 (Cynomolgus Monkey)

Gene Symbol

VSIG4

UniProt

Q9Y279-3

Additional VSIG4 Products

Product Documents for Recombinant Human VSIG4 Short Isoform His Tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human VSIG4 Short Isoform His Tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.